Huntington National Bank’s Autolus Therapeutics AUTL Stock Holding History

Huntington National Bank’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2	Hold	1	–	–	﹤0.01%	4169
2026 Q1	$1	Hold	1	–	–	﹤0.01%	4064
2025 Q4	$2	Hold	1	–	–	﹤0.01%	3927
2025 Q3	$2	Hold	1	–	–	﹤0.01%	3958
2025 Q2	$2	Hold	1	–	–	﹤0.01%	3961
2025 Q1	$2	Hold	1	–	–	﹤0.01%	3971
2024 Q4	$2	Hold	1	–	–	﹤0.01%	3975
2024 Q3	$4	Hold	1	–	–	﹤0.01%	3907
2024 Q2	$3	Hold	1	–	–	﹤0.01%	3883
2024 Q1	$6	Hold	1	–	–	﹤0.01%	3663
2023 Q4	$6	Hold	1	–	–	﹤0.01%	3561
2023 Q3	$2	Hold	1	–	–	﹤0.01%	3665
2023 Q2	$2	Sell	1 -1,500	-100%	-$3.56K	﹤0.01%	3614
2023 Q1	$2.76K	Hold	1,501	–	–	﹤0.01%	1876
2022 Q4	$2.85K	Hold	1,501	–	–	﹤0.01%	1710
2022 Q3	$3K	Hold	1,501	–	–	﹤0.01%	1778
2022 Q2	$4K	Hold	1,501	–	–	﹤0.01%	1758
2022 Q1	$6K	Hold	1,501	–	–	﹤0.01%	1713
2021 Q4	$8K	Buy	+1,501	New	+$9.01K	﹤0.01%	1626

Other funds holding AUTL

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Huntington National Bank's AUTL Position: Q2 2026 in Review

Huntington National Bank held its Autolus Therapeutics (AUTL) position steady in Q2 2026 at 1 share worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #4169.

Huntington National Bank first reported a position in AUTL in Q4 2021 and has held it in 19 quarters since. The position peaked at $8K in Q4 2021. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

Huntington National Bank held 1 share of Autolus Therapeutics worth $2 as of Q2 2026.
Huntington National Bank left its Autolus Therapeutics share count unchanged in Q2 2026.
Autolus Therapeutics made up ﹤0.01% of Huntington National Bank's portfolio in Q2 2026, its #4169 holding.
Huntington National Bank first reported a position in Autolus Therapeutics in Q4 2021 and has held it in 19 quarters since.
Huntington National Bank's Autolus Therapeutics position peaked at $8K in Q4 2021.
84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Huntington National Bank's 13F filing for Q2 2026, filed 13 Aug 2026.